RSV Testing Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Kits and Reagents, Instruments), By Method (Molecular Diagnostics, Immunoassays, Sequencing), By End-User (Public, Private), and Region Forecast 2020-2031

RSV Testing Market size was valued at US$ 1,079.5 million in 2024 and is expected to reach US$ 1,677.5 million by 2031, growing at a significant CAGR of 6.5% from 2025-2031. RSV stands for respiratory syncytial virus. It is an infection that affects the respiratory tract. Respiratory syncytial virus testing checks a fluid sample from the nose to see if the contagious RSV virus is causing symptoms of a respiratory infection. Increasing incidence of respiratory infections, rising neonatal population base, and high demand for in-vitro diagnostics & point of care facilities are among the key factors driving the market growth. With the rising incidences of chronic conditions worldwide, cases of respiratory infections are expected to increase. According to the Pan American Health Organization, RSV infection cases have considerably grown across the globe. In 2022, RSV circulation returned to pre-pandemic seasonal levels in most sub-regions of the Americas. Moreover, the rising frequency of respiratory syncytial virus diagnostic (RSV) disease, particularly in children under the age of two years, is driving the global market.

The market is expanding favourably due to increased infrastructure investments in the healthcare sector and increase in neonatal and pediatric healthcare expenditure. The market development is also being positively impacted by rising knowledge of the excellent survival rates following early diagnosis and the accessibility of diagnostic tools. Favorable government initiatives, including free diagnostics, awareness campaigns, and reimbursement policies further boost the market growth. However, stringent regulations and development of RSV diagnostics may hinder the growth of market.

Moreover, the product launches are propelling market growth. For instance, in 2022, Avellino Labs USA, Inc. launched AvellinoCoV2 - Respiratory Test, a multi-panel RT-PCR-based virus assay that accurately detects four viral infections in a single patient sample - COVID-19, respiratory syncytial virus (RSV), influenza A and influenza B. Thus, COVID-19 has had a positive impact on the growth of the market and is expected to continue to grow in the future. Further, the development of contemporary RSV detection systems, such as western blot, direct immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and real-time polymerase chain reaction (PCR), is anticipated to be facilitated by the emergence of advanced techniques, such as biotechnology and nanotechnology.

Key Developments: 

• In February 2025, Thermo Fisher Scientific received FDA 510(k) approval for its TaqPath COVID-19, Flu A, Flu B, and RSV Select Panel. This multiplex PCR test detects and differentiates SARS-CoV-2, flu A/B, and RSV in a single sample within three hours, streamlining diagnostics and assisting in clinical decisions during flu season.
• In April 2024, Simple HealthKit launched at-home diagnostic kits for Diabetes (HbA1c), Respiratory Wellness, and Sexual Wellness on Amazon.com. Their Respiratory Wellness kit uniquely covers Influenza A, B, and RSV. Backed by CLIA-certified labs, they offer reliable diagnostics, quick results, and follow-up care to detect conditions early and streamline treatment.
• In September 2024, Roche launched the Cobas Respiratory Flex test, which uses proprietary TAGS technology to detect up to 15 pathogens, including SARS-CoV-2, flu A/B, and RSV, in a single PCR test. Compatible with cobas systems, this high-performance solution simplifies diagnostics, accelerates results, and supports syndromic testing with targeted pathogen selection for optimized patient care.
• In May 2023, Hologic's Panther Fusion SARS-CoV-2/Flu A/B/RSV assay received FDA 510(k) clearance. This rapid molecular test detects and differentiates SARS-CoV-2, flu A/B, and RSV, providing results in about three hours. It processes over 1,000 samples in 24 hours, simplifying diagnosis and supporting personalized patient care to guide effective treatment decisions.
• In June 2022, BD (Becton, Dickinson, and Company) launched the BD MAX™ Respiratory Viral Panel (RVP), a CE-marked molecular test for SARS-CoV-2, Influenza A/B, and RSV. Using a single swab delivers results in two hours, simplifies diagnosis, reduces multiple tests, and boosts testing capacity during flu season.